SBPH - スプリング・バンク・ファ―マシュ―ティカルズ (Spring Bank Pharmaceuticals Inc.) スプリング・バンク・ファ―マシュ―ティカルズ

 SBPHのチャート


 SBPHの企業情報

symbol SBPH
会社名 Spring Bank Pharmaceuticals Inc (スプリング・バンク・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Spring Bank Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product SB 9200 for the treatment of viral diseases. The Company''s SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate SB 11285 as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).   スプリング・バンク・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、小分子核酸ハイブリッドまたはSMNH合成物を使用し、特定タンパク質の活性を目標とする。ウィルス性の病気の治療を中心に開発し、感染した細胞の中のタンパク質レチノイン酸誘導可能な遺伝子の活性化を目標とする。本社はマサチュ―セッツ州ホプキントン。   Spring Bank Pharmaceuticals, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.
本社所在地 35 Parkwood Drive Suite 210 Hopkinton MA 01748 USA
代表者氏名
代表者役職名
電話番号 +1 508-473-5993
設立年月日 37530
市場名 NASDAQ Small Cap
ipoyear 2016年
従業員数 21人
url www.springbankpharm.com
nasdaq_url https://www.nasdaq.com/symbol/sbph
adr_tso
EBITDA EBITDA(百万ドル) -25.46500
終値(lastsale) 13.94
時価総額(marketcap) 183800182.48
時価総額 時価総額(百万ドル) 224.12860
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 184.17360
当期純利益 当期純利益(百万ドル) -20.93900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Spring Bank Pharmaceuticals Inc revenues was not reported. Net loss decreased 44% to $8.6M. Lower net loss reflects Gain on change in fair value of warrant increase from $5.7M (expense) to $5.2M (income) Interest income increase from $79K to $332K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.62 to -$0.66.

 SBPHのテクニカル分析


 SBPHのニュース

   The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions  2020/11/08 17:47:42 Benzinga
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.
   ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm - AMAG, SBPH, VAR, SINA, GARS  2020/10/06 03:07:00 Benzinga
NEW YORK , Oct. 5, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Covis Group S.à r.l. for $13.75 per share in cash. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/amag-pharmaceuticals-inc-stock-merger-covis/ . Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH ) concerning potential violations … Full story available on Benzinga.com
   Spring Bank Class Action: Halper Sadeh LLP Announces Filing of Shareholder Class Action Lawsuit Against Spring Bank Pharmaceuticals, Inc.; Investors Are Encouraged to Contact the Firm - SBPH  2020/09/29 05:37:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) in connection with its merger with F-star Therapeutics Limited. The lawsuit seeks damages and/or equitable relief on behalf of Spring Bank shareholders under the federal securities laws. If you are a Spring Bank shareholder and would like to join the action, visit Spring Bank Class Action or contact Da
   SHAREHOLDER ALERT: WeissLaw LLP Investigates Spring Bank Pharmaceuticals, Inc.  2020/09/22 22:34:00 PR Newswire
NEW YORK, Sept. 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals, Inc. ("SBPH" or the "Company") (NASDAQ: SBPH) in connection with SBPH's July 29, 2020 merger and…
   ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - SBPH, VAR, JCAP, GLIBA  2020/09/03 07:11:00 PR Newswire
NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its…
   The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions  2020/11/08 17:47:42 Benzinga
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.
   ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm - AMAG, SBPH, VAR, SINA, GARS  2020/10/06 03:07:00 Benzinga
NEW YORK , Oct. 5, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Covis Group S.à r.l. for $13.75 per share in cash. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/amag-pharmaceuticals-inc-stock-merger-covis/ . Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH ) concerning potential violations … Full story available on Benzinga.com
   Spring Bank Class Action: Halper Sadeh LLP Announces Filing of Shareholder Class Action Lawsuit Against Spring Bank Pharmaceuticals, Inc.; Investors Are Encouraged to Contact the Firm - SBPH  2020/09/29 05:37:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) in connection with its merger with F-star Therapeutics Limited. The lawsuit seeks damages and/or equitable relief on behalf of Spring Bank shareholders under the federal securities laws. If you are a Spring Bank shareholder and would like to join the action, visit Spring Bank Class Action or contact Da
   SHAREHOLDER ALERT: WeissLaw LLP Investigates Spring Bank Pharmaceuticals, Inc.  2020/09/22 22:34:00 PR Newswire
NEW YORK, Sept. 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals, Inc. ("SBPH" or the "Company") (NASDAQ: SBPH) in connection with SBPH's July 29, 2020 merger and…
   ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - SBPH, VAR, JCAP, GLIBA  2020/09/03 07:11:00 PR Newswire
NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 スプリング・バンク・ファ―マシュ―ティカルズ SBPH Spring Bank Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)